Literature DB >> 9630681

Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.

Y M Kuo1, S Webster, M R Emmerling, A E Roher.   

Abstract

Experimental evidence increasingly implicates the beta-amyloid peptide in the pathogenesis of Alzheimer's disease. Beta-amyloid filaments dramatically accumulate in the neuritic plaques and vascular deposits as the result of the brain's inability to clear these structures. In this paper, we demonstrate that in addition to the intrinsic stability of A beta N-42, the time dependent generation of irreversibly associated A beta dimers and tetramers incorporated into A beta filaments are themselves resistant to proteolytic degradation. The presence of post-translational modifications such as isomerization of aspartyls 1 and 7, cyclization of glutamyl 3 to pyroglutamyl and oxidation of methionyl 35, further contribute to the insolubility and stability of A beta. All these factors promote the accumulation of neurotoxic amyloid in the brains of patients with Alzheimer's disease, and should be considered in therapeutic strategies directed towards the dissociation of the brain's A beta filaments. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630681     DOI: 10.1016/s0925-4439(98)00014-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  45 in total

1.  Molecular dynamics simulation of amyloid beta dimer formation.

Authors:  B Urbanc; L Cruz; F Ding; D Sammond; S Khare; S V Buldyrev; H E Stanley; N V Dokholyan
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

2.  Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation.

Authors:  Silvia Fossati; Krysti Todd; Krystal Sotolongo; Jorge Ghiso; Agueda Rostagno
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

Review 3.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

5.  Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.

Authors:  Eric M Reiman; Kewei Chen; Jessica B S Langbaum; Wendy Lee; Cole Reschke; Daniel Bandy; Gene E Alexander; Richard J Caselli
Journal:  Neuroimage       Date:  2009-07-23       Impact factor: 6.556

Review 6.  Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

7.  Neuron loss in transgenic mouse models of Alzheimer's disease.

Authors:  Oliver Wirths; Thomas A Bayer
Journal:  Int J Alzheimers Dis       Date:  2010-08-12

8.  The biochemical aftermath of anti-amyloid immunotherapy.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James Ar Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Mol Neurodegener       Date:  2010-10-07       Impact factor: 14.195

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.